Capital Analysts LLC
SYRE icon

Capital Analysts LLC’s Spyre Therapeutics SYRE Stock Holding History

Capital Analysts LLC’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$178 Buy
+2
New +$192 ﹤0.01% 1696

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
Affinity Asset Advisors
Affinity Asset Advisors New York $2.46B AUM 196.28% 1-Year Est. Return

Capital Analysts LLC's SYRE Position: Q3 2026 in Review

Capital Analysts LLC opened a new position in Spyre Therapeutics (SYRE) in Q3 2026: 2 shares worth $178. The stake represents ﹤0.01% of the portfolio and ranks #1696 among its holdings.

193 funds tracked by Wall St. Rank hold SYRE as of Q3 2026.

  • Capital Analysts LLC held 2 shares of Spyre Therapeutics worth $178 as of Q3 2026.
  • Spyre Therapeutics was a new Capital Analysts LLC position in Q3 2026.
  • Spyre Therapeutics made up ﹤0.01% of Capital Analysts LLC's portfolio in Q3 2026, its #1696 holding.
  • 193 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q3 2026.

Based on Capital Analysts LLC's 13F filing for Q3 2026, filed 13 Nov 2026.